Metronidazol Smartpractice Europe (Metronidazole)

Metronidazole is a Nitroimidazole antibiotic used topically for conditions involving anaerobic microorganisms or inflammatory skin disease.

• Rosacea: reduces inflammatory papules, pustules and erythema on the face.
• Anaerobic skin infections: helps eradicate susceptible anaerobic bacteria in localized lesions.
• Post‑operative wound care: applied to minor surgical or traumatic wounds to prevent bacterial colonisation.

• Metronidazole enters anaerobic bacterial and protozoal cells where its nitro group is reduced to reactive metabolites. These metabolites bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, ultimately leading to cell death. The selective reduction occurs under low‑oxygen conditions, sparing aerobic host cells.

Common Side Effects

• Skin irritation: mild redness or discomfort at the application site.
• Burning or stinging sensation during or after application.
• Itching or pruritus.
• Dryness or flaking of the treated skin.
• Mild erythema.
• Localized swelling.

Serious or Rare Side Effects

• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Severe skin necrosis or ulceration.
• Systemic toxicity if absorbed in large amounts (e.g., neurotoxicity, seizures).

Before using Metronidazol Smartpractice Europe, consider the following precautions:

• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Large or broken skin areas: avoid extensive application on extensive open wounds.
• Pregnancy: use only if the prescriber determines potential benefit outweighs risk.
• Alcohol: advise patients to avoid alcohol to prevent disulfiram‑like reactions.
• Concurrent anticoagulants: monitor coagulation parameters when used with warfarin.
• Storage: Store at room temperature: keep in the original container, protect from moisture and light.

Metronidazol Smartpractice Europe may interact with several systemic agents.

Major Interactions (Avoid)

• Alcohol: may cause severe flushing, nausea, and vomiting.
• Warfarin: potentiates anticoagulant effect, increasing bleeding risk.
• Lithium: may raise lithium serum concentrations, risking toxicity.
• Other nitroimidazoles: concurrent use can increase toxicity.

Moderate Interactions (Monitor Closely)

• Phenytoin: may reduce metronidazole plasma levels.
• Cimetidine: can increase metronidazole concentrations.
• Carbamazepine: may lower metronidazole efficacy.
• Anticonvulsants (e.g., valproic acid): monitor for altered drug levels.